Cardiologist Eric Topol takes a critical look at the peptide boom, noting that beyond GLP-1 receptor agonists — which have robust outcome data — most other peptides in the wellness market still lack proven health-outcome benefits. A useful framing for separating the evidence-backed class from the hype.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.